このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Youth Overdose & Use Reduction in Rural Systems (YOURS)

2026年9月22日 更新者:Kym Ahrens、Seattle Children's Hospital

YOURS Study: Youth Overdose & Use Reduction in Rural Systems

The goal of this study is to conduct a clinical trial to understand effects of providing multilevel intervention to young people in the legal system. The multilevel intervention includes flexible care management using ACRA/ACC principles, family support, and overdose education. This study aims to test the implementation strategy, as well as the outcomes of the intervention with participants.

The first question the study will address is how successful was implementation. This will be measured by the number of youth receiving case management, family support, naloxone supplies, and overdose prevention curricula, and adoption by the participating county court systems.

The second question the study will address is whether the intervention impacted youth behavioral outcomes, such as overdose risk awareness, knowledge of how to use naloxone, and number of days per month using substances.

Researchers will compare youth who received the intervention to youth who received usual treatment to see if the intervention increases overdose risk awareness and knowledge, and decreases frequency of substance use.

Participants will receive the intervention (if assigned to) and complete study surveys. Participating counties will provide data on implementation, and site visits will also be performed to track each county's performance.

調査の概要

詳細な説明

Youth involved in the legal system (YILS) have some of the highest rates of substance and opioid use disorders (SUD/OUD) nationally; but few have access to adequate resources to prevent serious sequelae. SUD prevention and overdose prevention interventions for YILS are critically important to delay escalation to synthetic opioids and prevent fatalities and other health, and legal consequences.

Washington State is facing an overdose crisis; between August 2022 and 2023, overdose deaths in this state increased by 40%, a steeper increase than any other state. Rural counties in this state report overdose rates that are as high or higher than urban ones. YILS, even those without OUD, are especially vulnerable to unintentional overdose; amongst YILS incarcerated in Washington State system completing a drug and alcohol assessment, 58% had experienced an overdose at some point in the past (unpublished data). Substance use resources in this and other states for rural YILS are critical and sparse.

Working with counties on a prevention strategy will further the goal of intervening with YILS who are, on average, earlier in the spectrum of legal and substance use involvement. Prior to this trial, the research team completed a codesign process with various stakeholders to design an intervention. Codesign invites people with lived experience to the design process with the goal of designing a more effective intervention. The codesign group consisted of youth and caregivers with lived experience with substance use or the juvenile court system, behavioral health providers, funding sector representatives, and juvenile county court administrators.Participating counties will be randomized into 6 clusters of the stepped wedge design. Control group participant data collection will begin for all counties at the same time. Clusters of counties will step into the implementation stage every 3-months. When counties move into the implementation stage, intervention group participant data collection will immediately begin.

研究の種類

介入

入学 (推定)

550

段階

  • 適用できない

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

14年~18年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Youth age 14-18
  • Current juvenile court-involvement or receiving services from a participating county court (includes detention, diversion, truancy, at-risk youth, etc.)
  • Received a REDCap link or QR code and study participation code from authorized county staff

Exclusion Criteria:

  • Youth age 13 and under
  • Youth who do not receive a study participation code from an authorized county contact
  • Unable to participate due to significant mental health or developmental issue precluding meaningful participation in study procedures and/or intervention

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:ヘルスサービス研究
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Intervention: YOURS Navigator Program

The intervention consists of a navigator stationed in each participating county or shared by neighboring counties. The navigator will deliver a flexible care management intervention, including direct services and referrals to court-involved youth in rural Washington counties.

Care Navigator who will work with youth and families to address mental health, substance use, and other unmet needs, both through direct support services as well as referrals to adjunctive agencies. The flexible care management intervention may include goal setting, skill building, contingency management, motivational interviewing, overdose prevention and education, mental health and substance first aid, and basic needs support. The Navigator will work closely with the youth for 3-months, and as-needed up to 6-months.

他の名前:
  • ケアマネジメント
  • ACRA/ACC
  • Assertive Continuing Care (ACC)
介入なし:Usual Care

No Navigator intervention during the control time period. The juvenile court system may refer adolescents to their usual care pathways.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Overdose Prevention Knowledge
時間枠:3- and 6-months

Youth knowledge on how to prevent and/or respond to an overdose. Assessed using the Opioid Overdose Knowledge Scale (OOKS). Scores range from 0-45 and a higher score is considered a better outcome.

3- and 6-months
Presence of use past 30 days (Yes/No)
時間枠:3- and 6-months

Use of any overdose associated substance (opioids, benzodiazepines, alcohol, or stimulants) in the past 30 days; use of any substance in the past 30 days

3- and 6-months
Number of days using alcohol and cannabis
時間枠:3- and 6-months

In the past 30 days, number of days youth used cannabis; in the past 30 days, number of days youth used alcohol.

3- and 6-months
Number of youth receiving case management, mental health, or substance use prevention services
時間枠:Through study completion, up to 30 months

Primary implementation outcome - county level

Through study completion, up to 30 months
Number of naloxone kits distributed
時間枠:Through study completion, up to 30 months

Primary implementation outcome - county level

Through study completion, up to 30 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of days of using other individual non-alcohol/non-cannabis substances
時間枠:3- and 6- months

Measure taken from the HEAL Prevention Cooperative Common Core Measures

3- and 6- months
Substance use refusal self-efficacy
時間枠:3- and 6-months

How confident youth are resisting substances.

3- and 6-months
Percent of youth reporting receipt of naloxone
時間枠:3 months

Percent of youth receiving naloxone, a medication to reverse an opioid overdose.

3 months
Number of youth receiving overdose prevention education
時間枠:Through study completion, up to 30 months

Secondary implementation outcome - county level

Through study completion, up to 30 months
Number of court staff receiving overdose prevention education
時間枠:Through study completion, up to 30 months

Secondary implementation outcome - county level

Through study completion, up to 30 months

その他の成果指標

結果測定
メジャーの説明
時間枠
Presence of non-fatal overdose
時間枠:3- and 6-months

Exploratory outcome, investigator-developed

3- and 6-months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月1日

一次修了 (推定)

2029年2月1日

研究の完了 (推定)

2029年2月1日

試験登録日

最初に提出

2026年7月16日

QC基準を満たした最初の提出物

2026年9月22日

最初の投稿 (実際)

2026年9月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月29日

QC基準を満たした最後の更新が送信されました

2026年9月22日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2026-007-SCH
  • R61DA061846 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified data will be shared with investigators who propose a specific data analysis plan that is reviewed and approved by study PIs, unless prohibited by NIDA, IRB, or another regulatory body (e.g., DSMB).

IPD 共有時間枠

IPD and supporting information will be available at the end of the study (March 2029) for up to 5 years (through February 2034).

IPD 共有アクセス基準

Investigators need to submit a brief description of how they will use the data to our team to access data and supporting information. Investigators will send a dataset once the project is approved.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する